PMID- 34894326
OWN - NLM
STAT- MEDLINE
DCOM- 20220114
LR  - 20220114
IS  - 1179-1918 (Electronic)
IS  - 1173-2563 (Linking)
VI  - 42
IP  - 1
DP  - 2022 Jan
TI  - Semaglutide and Diabetic Retinopathy Risk in Patients with Type 2 Diabetes 
      Mellitus: A Meta-Analysis of Randomized Controlled Trials.
PG  - 17-28
LID - 10.1007/s40261-021-01110-w [doi]
AB  - BACKGROUND: Semaglutide is a recently approved glucagon-like peptide-1 receptor 
      agonist used to treat patients with type 2 diabetes mellitus (T2DM). The 
      SUSTAIN 6 trial found a significantly higher rate of retinopathy complications in 
      the semaglutide-treated group compared with the placebo group. OBJECTIVE: This 
      study aimed to evaluate the association between semaglutide and the risk of 
      retinopathy in patients with T2DM. METHODS: Electronic databases were 
      systematically searched up to April 2021 to identify randomized controlled trials 
      that reported diabetic retinopathy (DR) events in semaglutide-treated and control 
      groups. A meta-analysis was conducted using Review Manager 5.4 software to 
      calculate the risk ratio (RR) and 95% confidence intervals (CIs). RESULTS: A 
      total of 23 randomized trials involving 22,096 patients with T2DM were included. 
      There were 730 incident DR cases-463 in the semaglutide group and 267 in the 
      control group. Overall, semaglutide was not associated with increased DR risk 
      compared with controls when all trials were combined (RR 1.14, 95% CI 0.98-1.33). 
      Subgroup analysis showed that semaglutide was associated with an increased risk 
      of DR compared with placebo (RR 1.24, 95% CI 1.03-1.50). Moreover, patient age 
      >/= 60 years and diabetes duration >/= 10 years were also factors for increased risk 
      of DR when using semaglutide (RR 1.27, 95% CI 1.02-1.59; RR 1.28, 95% CI 
      1.04-1.58, respectively). CONCLUSIONS: Semaglutide was not associated with an 
      increased risk of DR; however, caution regarding DR risk is needed for older 
      patients or those with long diabetes duration when taking semaglutide.
CI  - (c) 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
FAU - Wang, Feiyu
AU  - Wang F
AD  - Department of Pharmacy, The First Affiliated Hospital, Fujian Medical University, 
      Chazhong Road No. 20, Fuzhou, 350005, China.
FAU - Mao, Yinjun
AU  - Mao Y
AD  - Department of Pharmacy, The First Affiliated Hospital, Fujian Medical University, 
      Chazhong Road No. 20, Fuzhou, 350005, China.
FAU - Wang, Hang
AU  - Wang H
AD  - Department of Pharmacy, The First Affiliated Hospital, Fujian Medical University, 
      Chazhong Road No. 20, Fuzhou, 350005, China.
FAU - Liu, Yiwei
AU  - Liu Y
AD  - Department of Pharmacy, The First Affiliated Hospital, Fujian Medical University, 
      Chazhong Road No. 20, Fuzhou, 350005, China.
FAU - Huang, Pinfang
AU  - Huang P
AUID- ORCID: 0000-0002-2699-9663
AD  - Department of Pharmacy, The First Affiliated Hospital, Fujian Medical University, 
      Chazhong Road No. 20, Fuzhou, 350005, China. abstract2016@163.com.
LA  - eng
GR  - 2018QH1071/the Startup Fund for Scientific Research, Fujian Medical University/
GR  - JT180186/Fujian Youth Education Research Project/
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20211211
PL  - New Zealand
TA  - Clin Drug Investig
JT  - Clinical drug investigation
JID - 9504817
RN  - 0 (Hypoglycemic Agents)
RN  - 53AXN4NNHX (semaglutide)
RN  - 62340-29-8 (Glucagon-Like Peptides)
SB  - IM
MH  - *Diabetes Mellitus, Type 2/diagnosis/drug therapy/epidemiology
MH  - *Diabetic Retinopathy/chemically induced/diagnosis/drug therapy
MH  - Glucagon-Like Peptides
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects
MH  - Middle Aged
MH  - Randomized Controlled Trials as Topic
EDAT- 2021/12/12 06:00
MHDA- 2022/01/15 06:00
CRDT- 2021/12/11 12:11
PHST- 2021/11/24 00:00 [accepted]
PHST- 2021/12/12 06:00 [pubmed]
PHST- 2022/01/15 06:00 [medline]
PHST- 2021/12/11 12:11 [entrez]
AID - 10.1007/s40261-021-01110-w [pii]
AID - 10.1007/s40261-021-01110-w [doi]
PST - ppublish
SO  - Clin Drug Investig. 2022 Jan;42(1):17-28. doi: 10.1007/s40261-021-01110-w. Epub 
      2021 Dec 11.